United Kingdom Approves AstraZeneca Coronavirus Vaccine

(Photo by JUSTIN TALLIS/AFP via Getty Images)

Daily Caller News Foundation logo
Andrew Trunsky Political Reporter
Font Size:

The United Kingdom became the first country to approve AstraZeneca’s coronavirus vaccine as the nation combats a sharp spike in confirmed cases.

The vaccine, developed in partnership with Oxford University, can be stored at much warmer temperatures than other approved candidates. Its approval followed an official recommendation from Britain’s Medicines and Healthcare Products Regulatory Agency, and the country has already purchased 100 million doses, the company said in its statement.

“The rollout will start on Jan. 4 and will really accelerate into the first few weeks of next year,” British Health Secretary Matt Hancock told Sky News.

His comments were echoed by AstraZeneca CEO Pascal Soriot, who told BBC Radio that vaccines will be shipped Wednesday or Thursday and that vaccinations “will start next week and we will get to 1 million – and beyond that – a week, very rapidly.”

“[It’s] an important day for millions of people in the U.K. who will get access to this new vaccine,” Soriot added. “It has been shown to be effective, well-tolerated, simple to administer and is supplied by AstraZeneca at no profit.”

Like Pfizer’s vaccine, which was approved in the U.K. in early December, AstraZeneca’s also requires two doses. But health experts believe that the first dose will be powerful enough to protect against the virus, and have said that they will focus on administering the first dose to as many people as possible.

They added that everybody would receive their second dose within 12 weeks of receiving their first.

COVENTRY, ENGLAND - DECEMBER 08: "Bill" William Shakespeare, 81, receives the Pfizer/BioNTech covid-19 vaccine at University Hospital at the start of the largest ever immunisation programme in the UK's history on December 8, 2020 in Coventry, United Kingdom. More than 50 hospitals across England were designated as covid-19 vaccine hubs, the first stage of what will be a lengthy vaccination campaign. NHS staff, over-80s, and care home residents will be among the first to receive the Pfizer/BioNTech vaccine, which recently received emergency approval from the country's health authorities. (Photo by Jacob King - Pool / Getty Images)

“Bill” William Shakespeare, 81, receives the Pfizer/BioNTech covid-19 vaccine at University Hospital at the start of the largest ever immunization program in the UK’s history on December 8, 2020 in Coventry, United Kingdom. (Jacob King/Getty)

The vaccine’s approval follows record daily case counts in the U.K. worsened by a more contagious variant that originated in the country and is spreading across the globe. The strain prompted British Prime Minister Boris Johnson to impose a series of strict lockdown measures through the holidays and led several countries to fully halt travel to and from the country.

Scientists, however, believe that vaccines will be effective against the new strain.

“At the moment, there’s no evidence that the vaccines won’t work against the new variant,” Oxford’s Dr. Andrew Pollard told BBC. “But that is something which we have to look at. We can’t be complacent about this variant or perhaps future variants.” (RELATED: Here’s What We Know About The New Coronavirus Strain)

AstraZeneca’s Phase III trials showed the vaccine to be approximately 70% effective, though the drug maker said that one dosing regimen showed approximately 90% effectiveness.

The vaccine will likely be relied upon throughout the world since it can be stored in refrigerators instead of specialized ultra-cold freezers. The company also said that it plans to produce approximately 3 billion doses by the end of 2021.

“We have a vaccine for the world,” Pollard said on Wednesday.

All content created by the Daily Caller News Foundation, an independent and nonpartisan newswire service, is available without charge to any legitimate news publisher that can provide a large audience. All republished articles must include our logo, our reporter’s byline and their DCNF affiliation. For any questions about our guidelines or partnering with us, please contact